What Is Ipamorelin? How Growth Hormone Secretagogues Work

Ipamorelin is a synthetic five amino acid peptide that binds the ghrelin receptor and makes the pituitary gland release a short burst of your own growth hormone. It was created by a pharmaceutical research group in the 1990s and never finished clinical development. As of September 2026 it is not approved by the FDA for any use, and the published human evidence amounts to two studies: a pharmacology trial in a few dozen healthy men and a phase 2 surgical trial in 114 patients that failed to beat placebo on its main endpoint.

What ipamorelin is, and where it came from

Ipamorelin is a pentapeptide, meaning a chain of five amino acids. Its sequence is often written as Aib-His-D-2-Nal-D-Phe-Lys-NH2. Some of those building blocks are not the standard amino acids your body uses, which matters later: the FDA has noted that unnatural amino acids make a peptide harder to characterize and to check for impurities.

It was described in 1998 by a research team at Novo Nordisk, who built it out of a chemistry program based on an older compound called growth hormone-releasing peptide-1. The paper that introduced it called it the first selective growth hormone secretagogue. A growth hormone secretagogue is any drug that prompts your own pituitary gland to release growth hormone, as opposed to injecting growth hormone itself.

What selective meant in the original experiments

The 1998 work was done in rat pituitary cells, anesthetized rats, and conscious swine. In cell culture, ipamorelin released growth hormone with a potency of about 1.3 nanomolar, similar to the older peptide GHRP-6. In swine, the dose producing half the maximum effect was about 2.3 nanomoles per kilogram.

The interesting finding was what did not happen. In swine, none of the secretagogues tested changed FSH, LH, prolactin, or TSH. But GHRP-6 and GHRP-2 both raised ACTH and cortisol, the stress hormone axis, while ipamorelin did not raise them beyond what GHRH itself produced, even at doses more than 200 times higher than the dose needed for growth hormone release. That single result is the origin of nearly every marketing claim you will read about ipamorelin being cleaner than older peptides.

It is worth being precise about what that evidence is. It is a pig and rat study from 1998. It says ipamorelin, at those doses, in those animals, did not move cortisol. It does not tell you what happens to a person injecting it under the skin for months.

How growth hormone secretagogues work in the body

Growth hormone is not released steadily. Your pituitary puts out pulses, mostly at night, under the push and pull of two hypothalamic signals: growth hormone-releasing hormone, which drives release, and somatostatin, which suppresses it.

The ghrelin receptor and the growth hormone pulse

In 1999, researchers in Japan purified a stomach hormone they named ghrelin and showed it was the natural ligand for the receptor that synthetic secretagogues had been hitting all along. Ghrelin is the same hormone that drives hunger. Its receptor sits on pituitary somatotroph cells, on hypothalamic neurons, and in many other organs including the heart, pancreas, intestine, and adipose tissue.

Ipamorelin is a ghrelin mimetic. According to the FDA's own review, it works mainly by activating ghrelin receptors on growth hormone-releasing hormone neurons in the hypothalamus, which in turn drives growth hormone release from the anterior pituitary. Because it works through your pituitary rather than replacing the hormone, it can only do something if your pituitary still works. The FDA review makes this point directly: someone with complete growth hormone deficiency, with an absent or severely damaged pituitary, would not be expected to respond at all.

Why the effect is short lived

The only published human pharmacokinetic study, from 1999, infused ipamorelin intravenously over 15 minutes in healthy men. The drug had a terminal half-life of about two hours. The growth hormone response was a single episode that peaked at about 0.67 hours, roughly 40 minutes, and then declined to negligible levels at every dose tested.

That is the whole picture of the drug's action in humans: one pulse, then gone. A broader review of this drug class also noted that the growth hormone response to these peptides partially desensitizes, more so during continuous infusion and less during intermittent dosing.

Where IGF-1 fits in

Growth hormone does much of its work indirectly. It tells the liver and other tissues to make insulin-like growth factor 1, or IGF-1, which is more stable in the blood and is what clinicians usually measure. A single growth hormone spike is not the same thing as a sustained rise in IGF-1, and a rise in IGF-1 is not the same thing as a change in muscle, fat, or function. Each of those is a separate question needing its own evidence, and for ipamorelin, none of those questions has been answered in a published human trial.

How ipamorelin differs from GHRH analogs like sermorelin and tesamorelin

Peptides that raise growth hormone come in two main families, and they are often confused. Sermorelin, tesamorelin, and CJC-1295 are analogs of growth hormone-releasing hormone. They act on the GHRH receptor. Ipamorelin, GHRP-2, GHRP-6, hexarelin, and the oral drug ibutamoren act on the ghrelin receptor instead.

Both routes end in the same place, a pituitary growth hormone pulse, but the receptors, the side effect profiles, and the evidence behind them are different. Of the whole group, only a few have ever been approved drugs: tesamorelin is FDA approved for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, macimorelin is approved as a single-dose diagnostic test for adult growth hormone deficiency, and sermorelin was approved as Geref for pediatric use and is now listed in FDA records as discontinued, a change the agency determined was not made for safety or effectiveness reasons. If you are weighing the GHRH side of the family, the comparison in sermorelin versus recombinant growth hormone covers that in detail, and the evidence on tesamorelin and visceral fat covers the one GHRH analog with large trial data.

Why the two are marketed together, and how thin that reasoning is

Products sold today, whether compounded or supplier-sourced, often pair a ghrelin receptor agonist with a GHRH analog, most commonly ipamorelin with CJC-1295. The rationale is real pharmacology: a 1997 review of this drug class concluded that the growth hormone-releasing activity of these peptides is synergistic with that of GHRH. Pushing two different levers on the same pituitary cell does produce a bigger growth hormone pulse than either alone.

The gap is between that and a clinical claim. A bigger hormone spike is a laboratory result, not an outcome. A PubMed search in September 2026 found no published clinical trial of ipamorelin combined with a GHRH analog, let alone one measuring body composition, strength, recovery, sleep, or anything else patients care about. The FDA's 2024 review noted that a subject matter expert had described the ipamorelin plus CJC-1295 pairing as trending, and also noted the report contained no information on whether the combination produced any improvement.

What the human studies on ipamorelin actually show

There are two. That is the entire published human record, and both used intravenous dosing.

The phase 1 pharmacology study

Published in 1999, this was a randomized, placebo-controlled dose escalation study in healthy men. The FDA's review counts 48 enrolled subjects, while the paper's own abstract describes eight men at each of five dose levels, which would be 40. The doses were 4.21, 14.02, 42.13, 84.27, and 140.45 nanomoles per kilogram, given as a 15-minute intravenous infusion, and the FDA's review describes placebo subjects in each group.

The results were the pharmacology described above: dose-proportional kinetics, a half-life near two hours, a single growth hormone peak around 40 minutes, and negligible growth hormone by six hours. The lowest dose group produced growth hormone levels too small to model. The FDA's review of this paper noted it did not report any adverse events associated with ipamorelin, and that the subjects were healthy men with an intact pituitary axis.

What this study did not measure: muscle, fat, strength, sleep, injury recovery, IGF-1 over time, or any outcome over more than a single day. The FDA stated plainly that this study reported no effectiveness data for either diagnosing or treating growth hormone deficiency.

The postoperative ileus trial that missed

The second study, published in 2014, was a phase 2, multicenter, randomized, double-blind, placebo-controlled trial. It tested ipamorelin for postoperative ileus, the temporary shutdown of bowel movement that follows abdominal surgery. The rationale was the ghrelin receptor's role in gut motility, not growth hormone.

117 patients undergoing small and large bowel resection were enrolled and 114 were analyzed. They received 0.03 mg per kilogram of ipamorelin or placebo intravenously twice a day, starting the day after surgery and continuing up to seven days or discharge.

The 7.3 hour difference in the primary endpoint was not statistically significant, and the trial also found no significant differences on its secondary endpoints, including time to recovery of gut function and length of stay. The authors concluded the drug was well tolerated at that dose but that there were no significant differences between ipamorelin and placebo.

Two patients in the ipamorelin group died. Both had bowel resection for colon cancer and developed an anastomotic leak, a breakdown at the surgical join. As the FDA's review summarizes it, one death was from hyperkalemia in a patient with aortic clots, sepsis, a perforated ulcer, and renal failure, and the other was from sepsis in a patient with pneumonia. Whether ipamorelin contributed is unclear, and the placebo group had a similar overall rate of serious events. The FDA nonetheless flagged those deaths, along with the higher rates of low potassium and high blood sugar in the treated group, as raising safety concerns about compounding with ipamorelin.

A later review cited by the FDA summarized the outcome bluntly: because the trial showed no significant difference in measurable colonic function, development of ipamorelin was discontinued. A PubMed search in September 2026 turned up no later clinical trial of ipamorelin.

The dose nobody has studied

Whatever its source, a compounding pharmacy, a peptide supplier, or the gray market, ipamorelin is injected under the skin. A 2026 endocrinology review of performance peptides found that the regimens people follow come from bodybuilding forums, not from trials: several injections a day under the skin, often stacked with CJC-1295, in repeated multi-week cycles. None of those regimens has been tested in a clinical study.

Both published human studies used intravenous dosing. The FDA stated it found no pharmacokinetic or pharmacodynamic information for the subcutaneous route, and no safety data for it either. The 2026 review placed ipamorelin in an evidence tier defined by phase 1 human data without controlled efficacy data for body composition or performance outcomes.

What the animal work shows, and what it does not

The preclinical file is larger than the human file, and it is more mixed than the marketing suggests.

• In adult female rats given ipamorelin three times daily for 15 days, longitudinal bone growth rose in a dose-dependent way, from 42 micrometers per day in controls to 52 at the highest dose. Total IGF-I levels did not change.
• In young adult female rats treated for 12 weeks, ipamorelin and GHRP-6 raised bone mineral content, but the authors concluded this was due to the bones growing larger, not denser: volumetric bone mineral density was unchanged.
• In rats given a glucocorticoid for three months, adding ipamorelin counteracted the drug-induced loss of muscle strength and bone formation. That is a model of steroid-induced catabolism, not of healthy aging.
• In mice, secretagogues including ipamorelin increased body fat through a mechanism independent of growth hormone, along with higher food intake and leptin. Growth hormone itself did the opposite in the same experiment.
• In rats with surgically induced ileus, repeated intravenous ipamorelin improved stool output, food intake, and weight gain. That finding is what led to the human trial that then failed.

Animal results in this field have a poor record of transferring. The rodent ileus data looked convincing and the human trial did not replicate it.

What related secretagogues did when they were properly tested

Because ipamorelin itself was never tested for body composition in people, the most honest way to estimate the ceiling of this drug class is to look at close relatives that were tested in large trials.

Ibutamoren (MK-677), an orally active ghrelin receptor agonist, was studied in 65 healthy adults aged 60 to 81 in a two-year randomized trial. It restored growth hormone and IGF-1 to young adult levels. Fat-free mass rose 1.1 kg in the treated group versus a 0.5 kg fall on placebo. But there was no improvement in strength or function, limb fat rose more than placebo, fasting glucose rose by about 5 mg/dL, insulin sensitivity fell, and cortisol rose slightly. The FDA separately notes a randomized trial of ibutamoren in hip fracture recovery that was stopped early over a possible congestive heart failure signal.

Anamorelin, another ghrelin receptor agonist, was tested in two phase 3 trials totaling 979 patients with lung cancer and cachexia. Lean body mass rose significantly compared with placebo, by roughly 0.65 to 0.99 kg over 12 weeks. Handgrip strength did not improve in either trial.

The pattern across both is consistent and worth internalizing: activating this receptor reliably moves hormone levels and moves lean mass on a scan, and it has repeatedly failed to move strength or function. Anyone promising you strength, performance, or recovery benefits from ipamorelin is promising something the better-studied members of its own drug class did not deliver.

Regulatory status as of September 2026

This is the part that changes most often, so here is the state of it, with dates.

FDA approval

Ipamorelin is not approved by the FDA for any indication, and it is not a component of any FDA-approved drug. There is no United States Pharmacopeia monograph for either ipamorelin free base or ipamorelin acetate, which means there is no official public standard defining what the ingredient must contain.

Compounding status

Compounding pharmacies can only work from bulk ingredients that meet certain conditions. Ipamorelin does not meet them.

• On September 29, 2023, the FDA placed ipamorelin acetate in Category 2 of its interim policy for outsourcing facilities under section 503B, the category for substances the agency has identified as presenting significant safety risks. The FDA has stated it would consider taking action against a compounder using a Category 2 substance. That listing was still current on the FDA's page as of its April 22, 2026 update.
• Under section 503A, the pathway for traditional compounding pharmacies, ipamorelin acetate was also a Category 2 substance until its nominators withdrew the nomination. The FDA's safety-risk page, current as of April 22, 2026, now lists it among substances that were nominated but withdrawn, still publishes the same safety concerns beside it, and notes that it remains in Category 2 under the 503B policy. The agency's 503A category list, updated May 14, 2026, does not show ipamorelin in any category. The FDA pages reviewed for this article do not give the date of the withdrawal. A withdrawn nomination is not a clearance: ipamorelin is not in Category 1, the only category covered by the agency's enforcement discretion, and it is not on the 503A bulks list.
• On October 29, 2024, the FDA's Pharmacy Compounding Advisory Committee voted on whether ipamorelin free base and ipamorelin acetate should be placed on the 503A Bulks List. For each form the vote was 0 in favor, 12 against, 1 abstention. Members cited a lack of information supporting safety and efficacy in the available data. One member noted that a drug being prescribed frequently does not make it safe and effective.

The FDA's own written recommendation to that committee concluded that a balancing of the criteria weighed against placing either form on the list, citing poor physical and chemical characterization, no data supporting effectiveness for either evaluated use, and unresolved safety concerns.

Compounding is not the only route by which ipamorelin reaches patients. Some physicians source it from peptide suppliers that sell third-party-tested product with a certificate of analysis and reconstitute it in their own office. That route is not FDA reviewed either, and the FDA's findings above concern the substance and its data, not just the pharmacy preparing it: there is still no approved use, no published subcutaneous dosing data, and no toxicity studies, whichever way it is sourced.

Anti-doping status

Ipamorelin is named on the World Anti-Doping Agency Prohibited List under section S2.2.4, growth hormone releasing factors, alongside anamorelin, capromorelin, ibutamoren, ghrelin, macimorelin, and tabimorelin. Substances in class S2 are prohibited at all times, in and out of competition, and the list identifies all of them as non-specified substances. GHRH analogs including sermorelin, tesamorelin, and CJC-1295 are listed in the same subsection. If you compete in a tested sport, at any level with an anti-doping program, this is disqualifying.

Risks, side effects, and the size of the unknowns

Honest risk information here has two parts: the short list of things actually observed in people, and the much longer list of things nobody has looked for.

What was observed in the one controlled trial

In the 2014 surgical trial, most adverse events were mild to moderate and generally related to the surgery itself. Nausea, vomiting, and abdominal distention were the most common and were numerically lower in the ipamorelin group. Low potassium, insomnia, and hyperglycemia at discharge were each more common with ipamorelin than placebo, as shown in the table above. Three patients on ipamorelin stopped treatment because of nausea, high blood pressure, or low blood pressure.

Post-marketing reports are almost nonexistent because there is no approved product. An FDA search of its adverse event database through September 2023 found just two non-serious reports involving compounded ipamorelin: a man who developed eye watering and headache after 17 days of a compounded nasal spray, and a man who developed elbow joint pain after two months of a compounded ipamorelin and sermorelin injection that did not fully resolve after stopping. The FDA cautioned that these reports cannot establish causation, and also noted the first product came from a website that sold through a payment app and, per the reporter, appeared structured to avoid detection.

Risks carried by anything that raises growth hormone

The FDA's review made the case that ipamorelin should be presumed to carry the risks already listed on approved growth hormone products until someone shows otherwise. Those labeled warnings include:

• Increased risk of neoplasm, meaning new tumor growth
• Glucose intolerance and diabetes
• Fluid retention
• Intracranial hypertension, or raised pressure around the brain
• Hypoadrenalism and hypothyroidism, meaning unmasked deficiencies in other hormone systems
• Pancreatitis
• In children, slipped capital femoral epiphysis and worsening of existing scoliosis

The cancer concern is theoretical rather than demonstrated for ipamorelin, but it is not fanciful: IGF-1 promotes cell growth and discourages cell death, which is why growth hormone products carry the neoplasm warning at all. A 2026 review of these peptides described the mitogenic implications via IGF-1 as biologically plausible but with no direct evidence of carcinogenesis from clinical studies, because the relevant clinical studies do not exist.

There is also a class precedent for cardiac effects: macimorelin, the one approved ghrelin receptor agonist, prolongs the QTc interval by about 11 milliseconds and its label warns against combining it with other QT-prolonging drugs. Nobody has measured what ipamorelin does to the QT interval.

Immunogenicity, aggregation, and impurities

Peptides can clump together, and clumps can trigger an immune response. The FDA's concern with ipamorelin is that it contains unnatural amino acids that complicate characterization, that critical data on impurities, aggregates, and bacterial endotoxins were not found in the published literature, and that the certificate of analysis submitted with the nomination lacked those tests.

Subcutaneous injection, the route people actually use, is generally associated with more immunogenicity than intravenous injection. One consequence of an immune response to a peptide is antibodies that neutralize not only the drug but the body's own version of it. That risk has never been measured for ipamorelin, in any route, in any study.

The studies that were never done

This is the most important part of the safety picture, and it is easy to miss because absence of data reads as absence of problems. At the time of its 2024 evaluation, the FDA reported that it could not find, in the publicly available literature, any of the following for ipamorelin:

• Acute toxicity studies
• Repeat-dose toxicity studies
• Genotoxicity studies, which test for DNA damage
• Developmental and reproductive toxicity studies
• Carcinogenicity studies
• Any pharmacokinetic study by the subcutaneous route, in animals or people

Two indirect signals are worth knowing. In mice, either activating or blocking the ghrelin receptor harmed fertilization, implantation, and fetal development, which the FDA flagged as a possible class effect that has not been ruled out for ipamorelin. And ghrelin receptors are present in brain reward circuits, where ghrelin increases dopamine release in animals and increases activity in reward regions in human imaging studies. The FDA raised the possibility that a ghrelin receptor agonist could have reinforcing properties, while stating the existing studies were insufficient to demonstrate whether ipamorelin does.

Product quality in the gray market

Much of what is sold as ipamorelin is labeled for research use only and sold by vendors with no pharmacy accountability. Forensic chemists analyzing seized black market growth promoting products have found not only the expected peptides but modified analogs, including a version of ipamorelin carrying an extra glycine at one end, which is not what the label says.

The broader pattern for injectable peptides bought online is well documented. In one investigation of unlicensed online sellers of a different injectable peptide drug, every purchased vial was judged probably substandard or falsified, all samples carried detectable endotoxin, and measured purity ranged from about 8 to 14 percent against a labeled claim of 99 percent. That study was about a different molecule, but it illustrates what an unregulated supply chain for an injectable peptide looks like. Sterility and endotoxin matter for anything you put under your skin.

Rx2BFIT sources its ipamorelin from a supplier whose batches are tested by an independent laboratory for identity and purity, keeps the certificate of analysis on file, and reconstitutes it in the office under Dr. Patel's supervision. It is not an FDA-approved medication, and that, along with the known risks and the limits of the evidence, is reviewed with every patient before starting.

When to seek urgent care

If you are using any injectable peptide, whether it came from a pharmacy, a physician's office, or a gray-market seller, get medical attention promptly for spreading redness, swelling, warmth, or pus at an injection site, fever or chills, severe or persistent abdominal pain, repeated vomiting, or signs of very high blood sugar such as intense thirst with frequent urination and confusion. Call emergency services for chest pain, fainting, a fast or irregular heartbeat, sudden severe headache with vision change, or any swelling of the face, lips, or throat, or difficulty breathing after an injection.

Who has the most reason to avoid it

Nobody can tell you from an article whether a drug is safe for you, and ipamorelin's evidence base cannot support a clean list of contraindications the way an approved drug's label does. But several groups carry clearly elevated risk, based on what growth hormone and ghrelin receptor activity do.

• Anyone with active or recent cancer. Growth hormone products carry a neoplasm warning, and IGF-1 signaling promotes cell proliferation. Nothing is known about ipamorelin in this setting.
• People with diabetes, prediabetes, or insulin resistance. Growth hormone opposes insulin. In the surgical trial, hyperglycemia at discharge was more common with ipamorelin, and in the two-year ibutamoren trial, fasting glucose rose and insulin sensitivity fell.
• Anyone pregnant, breastfeeding, or trying to conceive. There are no human reproductive data, and ghrelin receptor manipulation harmed fertilization and fetal development in mice.
• Children and adolescents. Growth plates, scoliosis progression, and hip growth plate problems are specific labeled risks of growth hormone products in children, and there is no pediatric data on ipamorelin.
• Competitive athletes in any tested sport. Prohibited at all times under the WADA list.
• People with untreated pituitary, thyroid, or adrenal disease. Raising one hormone axis can unmask deficiencies in others, and growth hormone deficiency itself needs a proper diagnosis with stimulation testing rather than a trial of a secretagogue.

If the underlying question is whether you have a real growth hormone problem, that is a diagnosis with an established workup: typically at least two stimulation tests using different agents, interpreted alongside IGF-1 and clinical findings. If the answer is genuine deficiency, approved replacement products exist and they work regardless of whether your pituitary still functions. You can read more about what is and is not established across this category on the peptide therapy overview and the tesamorelin and ipamorelin treatment page.

Myths and what the evidence actually supports

Myth: it is safer because it boosts your natural growth hormone rather than adding a hormone

The final signal is the same hormone at the receptor. Whether growth hormone reaches your tissues because you injected it or because your pituitary released it, IGF-1 rises and the downstream effects follow. The FDA's position is that risks listed on growth hormone labels should be presumed to apply until data show otherwise. The difference is that growth hormone products have decades of safety monitoring and ipamorelin has none.

Myth: the lack of cortisol effect means it has no hormonal side effects

The cortisol finding came from swine in 1998 and it was a comparison against other peptides, not proof of a clean profile. Blood sugar, fluid balance, potassium, and sleep were all disturbed more often than placebo in the one controlled human trial, and nothing else has been measured systematically.

Myth: stacking with a GHRH analog is proven to work better

The synergy is real at the level of the growth hormone pulse. No trial has tested whether that translates into any clinical benefit, and no trial has tested the combination's safety. Combining two unapproved peptides multiplies the unknowns rather than resolving them.

Myth: research use only labeling means it is legal to use

That labeling exists to avoid drug regulation, not to confer permission. In the US, ipamorelin is not approved, is not on the list of substances allowed for 503A compounding, and is in the FDA's Category 2 for outsourcing facilities. According to the FDA's 2024 review, Australia's medicines scheduling committee added it to that country's poisons standard under performance and image enhancing drugs, for which possession without legal authority such as a prescription is illegal. And in sport, it is banned at all times.

Reality: it does reliably produce a growth hormone pulse

This is the one claim that is solidly supported. In healthy men, ipamorelin produced a clear, dose-related growth hormone release with a peak near 40 minutes. Everything beyond that, about body composition, recovery, sleep, aging, or injury, remains untested in humans.

Questions worth asking your doctor

1. Do I have a documented growth hormone problem, and if so, what testing established it?
2. What specific outcome are we aiming for, and what human evidence supports ipamorelin producing that outcome?
3. Since ipamorelin is not FDA approved and not on the 503A bulks list, where is this product being made and what testing has the source done for identity, purity, sterility, and endotoxin?
4. What will we monitor while I am on it, how often, and what result would make us stop?
5. How does this interact with my other conditions and medications, particularly anything affecting blood sugar, blood pressure, or heart rhythm?
6. What approved treatments exist for what I am trying to fix, and what would a trial of those look like first?
7. If I compete in a tested sport, does this create an anti-doping violation for me?
8. What is the plan if nothing changes after a defined period, and how will we decide that objectively rather than by how I feel that week?

A prescriber who can answer all of those, and who is candid that the human evidence is two studies and neither one measured what you are hoping for, is giving you the information you need to make a real decision. That is the standard worth holding out for.

This is general information, not medical advice. Whether a treatment is right for you is determined by a licensed provider after an evaluation.